After strong preclinical testing results, Cybin is looking to advance CYB003 into a Plase 1/2a clinical trial, estimated for mid-2022.
Novamind Expands Group Therapy Model
Novamind announces plans to expand group therapy within its clinical therapy model.
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
Mydecine reports conditional approval to commence a Phase IIb study on smoking cessation, in partnership with Johns Hopkins University.
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease
Pharmather reports positive tolerability and dose-finding results in its clinical trial of a ketamine-based drug for Parkinson's disease as it prepares for a Phase III trial.
The War AGAINST Mental Health: 50 Years Of Failure And Corruption
For 50 years Western governments have relentlessly undermined the mental health of their citizens while also criminalizing the only effective drugs for treating mental health.
Revitalist Launches UNIT Initiative Working With Veteran and First Responder Non-Profits Across the United States Creating Nationwide Guidelines
Revitalist Lifestyle and Wellness announces a new initiative focusing on providing access to mental health therapies for veterans and first-responders.
Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant
Wesana Health reports positive treatment results in combining traditional antidepressants with psilocybin-based therapy.
Awakn Life Sciences Announces Closing of Private Placement
Awakn Life Sciences announces closing a a CAD $3.25 million private placement, with units priced at $1.60 along with a half-warrant with an exercise price of $2.20.
Red Light Holland Successfully Imports Psilocybin iMicrodose Packs into St. Vincent and the Grenadines Under a First-Ever Authorized Import Approval Process by the Country's Bureau of Standards and the Ministry of Health
Red Light Holland announces the first-ever import of psilocybin mushrooms into St. Vincent and the Grenadines.
How Capital Markets Are Fueling Psychedelic Medicine Growth
The psychedelic medicine industry is growing.
Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
Awaken receives regulatory approval to begin ketamine-based therapies in its flagship London mental health clinic.
MINDCURE Provides Update on Strategic Review
MINDCURE announces the completion of its strategic review and new cost saving measures.
